Trials / Suspended
SuspendedNCT00333307
Evaluation of the Safety of Relaxin in Preeclampsia
A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies · Industry
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
Detailed description
The effects of relaxin may be beneficial in the treatment of women with preeclampsia. This study will preliminarily evaluate the maternal, fetal and neonatal safety and tolerability of an IV infusion of relaxin compared with placebo given to women with severe preeclampsia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human relaxin |
Timeline
- Start date
- 2006-10-01
- First posted
- 2006-06-05
- Last updated
- 2010-03-16
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00333307. Inclusion in this directory is not an endorsement.